An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)
暂无分享,去创建一个
K. Chayama | N. Sugimoto | K. Muro | Y. Komatsu | S. Hironaka | K. Hirata | M. Tsuda | H. Kawakami | H. Hirano | H. Hara | T. Esaki | N. Machida | S. Kadowaki | H. Yabusaki | A. Makiyama